MXB Biotechnologies focuses on tumor pathology diagnosis in China, offering a range of diagnostic services including immunocytochemistry and molecular pathology. Their leading products are immunohistochemical detection instruments and a series of reagents. In June 2020, BSBE acquired a majority stake in MXB Biotechnologies, enabling medical institutes to improve detection accuracy and reduce costs.